What Happened

ADARx Pharmaceuticals priced its Nasdaq IPO at the top of its range, selling 26.3 million shares at $17 each for gross proceeds of $446.3 million—exceeding its initial $350 million target. AbbVie concurrently invested $100 million in a private placement for 4.9% of the biotech. Fellow RNA-focused biotech City Therapeutics also filed for a Nasdaq IPO, though terms have not yet been disclosed.

Who Is Affected

ADARx, a San Diego-based RNA therapeutics company with 100 employees and five clinical or advanced preclinical candidates, is the primary beneficiary. AbbVie, which already had a $335 million upfront partnership, deepened its stake. City Therapeutics, another RNAi biotech, is now pursuing its own public listing. Vendors serving clinical-stage biotechs—especially those offering clinical trial management, regulatory affairs software, or pre-commercial planning tools—should view this as a trigger to engage ADARx while capital is fresh.

Market Impact

• ADARx now has $546M in combined IPO and private placement capital to advance its siRNA pipeline through key data milestones and into phase 3 trials.
• The company plans to fund pre-commercial activities for onvuzosiran (phase 3 for hereditary angioedema) and initiate phase 2 studies for agazisiran across multiple complement-mediated diseases.
• City Therapeutics' IPO filing signals continued investor appetite for RNAi platforms, creating a secondary sales trigger for vendors targeting emerging public biotechs.
• ADARx's 100-person headcount is expected to grow as it scales clinical operations and prepares for potential commercialization.

What to Watch

Key milestones include phase 2 data for agazisiran in complement-mediated diseases (2027-2028), phase 3 progress for onvuzosiran, and IND filings for obesity program ADX-077 and Alzheimer's candidate ADX-199 in 2027. City Therapeutics' IPO pricing and timing will provide additional market signals for RNAi-focused vendors.

Related coverage

• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• ADARx plans IPO to fund siRNA therapies
• Iambic Therapeutics files for IPO, prioritizing HER2 inhibitor IAM1363
• Inflammation biotech Electra raises $350M in upsized Nasdaq IPO